Michaeli, D., & Michaeli, C. T. (2024). Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price. Journal of the National Comprehensive Cancer Network, 22(4), . https://doi.org/10.6004/jnccn.2023.7110
Chicago-Zitierstil (17. Ausg.)Michaeli, Daniel, und Christoph T. Michaeli. "Breakthrough Therapy Cancer Drugs and Indications with FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price." Journal of the National Comprehensive Cancer Network 22, no. 4 (2024). https://doi.org/10.6004/jnccn.2023.7110.
MLA-Zitierstil (9. Ausg.)Michaeli, Daniel, und Christoph T. Michaeli. "Breakthrough Therapy Cancer Drugs and Indications with FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price." Journal of the National Comprehensive Cancer Network, vol. 22, no. 4, 2024, https://doi.org/10.6004/jnccn.2023.7110.